Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients
Public ClinicalTrials.gov record NCT02772731. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Randomized Controlled Trial of Routine Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Breast cancer is the most common malignancy affecting women in the US. Surgical management is the mainstay of therapy, and in general consists of resection of the primary tumor with either a partial mastectomy (aka "lumpectomy") or a total mastectomy. The investigators hypothesize that routine shave margins during partial mastectomy will significantly reduce positive margin rate. A positive margin means that cancerous cells were detected at the edge of the excised area. This generally mandates a return to the operating room for re-excision.
Study identification
- NCT ID
- NCT02772731
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Interventions
- Partial mastectomy plus additional Shave Margin Procedure
- Partial mastectomy Procedure
Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2016 (Type not available)
- Primary completion
- Jun 2018 (Actual)
- Completion
- Nov 2024 (Actual)
- Last update posted
- Jan 31, 2025
2016 – 2024
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Loma Linda University Cancer Center | Loma Linda | California | 92354 | — |
| Watson Clinic Cancer and Research Center | Lakeland | Florida | 33805 | — |
| William Beaumont Hospital | Troy | Michigan | 48085 | — |
| UNC Chapel Hill | Chapel Hill | North Carolina | 27599-7213 | — |
| Wake Forest School of Medicine | Winston-Salem | North Carolina | 27157 | — |
| Cleveland Clinic Akron General | Akron | Ohio | 44307 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Women & Infants Hospital | Providence | Rhode Island | 02905 | — |
| Doctors Hospital at Renaissance | Edinburg | Texas | 78539 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02772731, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 31, 2025 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02772731 live on ClinicalTrials.gov.